CHAPEL HILL, N.C., May 22 /PRNewswire/ -- Pharmaceutical and biotech
companies increasingly are adopting a Risk-Based Approach (RBA) in their
Quality Assurance (QA) functions. This benchmarking study will help R&D
Quality Assurance executives tackle two current challenges:
-- Optimizing limited QA staff resources so that they have the most
-- Optimizing services in regards to the FDA's Risk-Bases method for
selecting inspection sites
The study assesses the size of QA organizations relative to the size of the R&D functional areas they serve. Organizations are also evaluated on their implementation of Risk-Based Approach and its impact on QA workload and management.
For specific research topic included in the study download a complimentary sample of this research, "Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry," at http://www3.best-in-class.com/br128.htm .
"Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry" reflects the type of research Best Practices, LLC conducts for members of its Business Excellence Board ( http://www3.best-in-class.com/beb ), a research and advisory service for health care and pharmaceutical executives.
For information on other services by Best Practices, LLC and its Business Excellence Board, contact Cameron Tew at email@example.com or 919-403-0251, ext. 246.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved